Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.57 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24338533 | 0.96 | GRIN2B (0.54) | GRIN2BGRIN2CNTSR1 | |
| SCHEMBL24339073 | 0.91 | GRIN2B (0.47) | GRIN2BGRIN2CNTSR1JAK3 | |
| SCHEMBL24338580 | 0.90 | GRIN2B (0.55) | GRIN2BGRIN2CNTSR1 | |
| SCHEMBL24620368 | 0.90 | GRIN2B (0.55) | GRIN2BGRIN2CNTSR1 | |
| Nyx-2925 SCHEMBL17712358 | 0.90 | GRIN2B (0.70) | GRIN2BGRIN2CJAK3 | |
| Nyx-2925 SCHEMBL19614471 | 0.90 | GRIN2B (0.70) | GRIN2BGRIN2CJAK3 | |
| Nyx-2925 SCHEMBL19614447 | 0.90 | GRIN2B (0.70) | GRIN2BGRIN2CJAK3 | |
| Nyx-2925 SCHEMBL18119906 | 0.90 | GRIN2B (0.70) | GRIN2BGRIN2CJAK3 | |
| Nyx-2925 SCHEMBL18119905 | 0.90 | GRIN2B (0.70) | GRIN2BGRIN2CJAK3 | |
| Risevistinel SCHEMBL18121976 | 0.90 | GRIN2B (0.70) | GRIN2BGRIN2CJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2023-10-05 | — | — | US | disclosed |
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2023-10-05 | — | — | US | disclosed |
| US-11530223-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220220119-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-07-14 | — | — | US | disclosed |
| US-11299495-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299495-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885NTSR1 231/4885 |
| US-11530223-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885NTSR1 231/4885 |
| US-20220220119-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885NTSR1 231/4885 |
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885NTSR1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.